UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
For
the quarterly period ended
OR
For the transition period from ________ to ________
Commission file number
(Exact name of registrant as specified in its charter)
| British Columbia | ||
(State or other jurisdiction of incorporation or organization) |
(I.R.S. employer identification no.) | |
| (Address of principal executive offices) | (Zip code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
None.
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large Accelerated Filer | ☐ | ☒ | |
| Non-Accelerated Filer | ☐ | Smaller Reporting Company | |
| Emerging Growth Company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financing accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐
As of October 31, 2022, the registrant had Class B Subordinate Voting Shares outstanding.
MEDMEN ENTERPRISES, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 24, 2022
TABLE OF CONTENTS
i
Use of Names
In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms “we,” “us,” “our,” “Company,” “Corporation” or “MedMen” refer to MedMen Enterprises Inc. together with its wholly-owned subsidiaries.
Disclosure Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains statements that we believe are, or may be considered to be, “forward-looking statements”. All statements other than statements of historical fact included in this document regarding the prospects of our industry or our prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as “may,” “will,” “expect,” “intend,” “estimate,” “foresee,” “project,” “anticipate,” “believe,” “plan,” “forecast,” “continue” or “could” or the negative of these terms or variations of them or similar terms. Furthermore, forward-looking statements may be included in various filings that we make with the Securities and Exchange Commission (the “SEC”), press releases or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. These known and unknown risks include, without limitation: marijuana remains illegal under U.S. federal law, and enforcement of cannabis laws could change; the Company may face limitations on ownership of cannabis licenses; the Company may become subject to U.S. Food and Drug Administration or the U.S. Bureau of Alcohol, Tobacco and Firearms; the Company may face difficulties acquiring additional financing; the Company operates in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business; the Company is subject to general economic risks; the Company may be negatively impacted by challenging global economic condition; the Company is subject to risks arising from epidemic diseases, such as the recent outbreak of COVID-19; the Company may face difficulties in enforcing its contracts; the Company is subject to taxation in Canada and the United States; cannabis businesses are subject to unfavorable tax treatment; cannabis businesses may be subject to civil asset forfeiture; the Company is subject to proceeds of crime statutes; the Company faces security risks; competition for the acquisition and leasing of properties suitable for the cultivation, production and sale of medical and adult use cannabis may impede our ability to make acquisitions or increase the cost of these acquisitions, which could adversely affect our operating results and financial condition; the Company faces risks related to its products; the Company is dependent on the popularity of consumer acceptance of the Company’s brand portfolio; the Company faces risks related to its insurance coverage and uninsurable risks; the Company is dependent on key inputs, suppliers and skilled labor; the Company must attract and maintain key personnel; the Company’s business is subject to the risks inherent in agricultural operations; the Company’s sales are difficult to forecast; the Company’s products may be subject to product recalls; the Company may face unfavorable publicity or consumer perception; the Company faces intense competition; and additional issuances of Subordinate Voting Shares may result in dilution. Further information on these and other potential factors that could affect the Company’s business and financial condition and the results of operations are included in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the SEC on September 9, 2022, and elsewhere in the Company’s filings with the SEC, which are available on the SEC’s website or on the Company’s website at https://investors.medmen.com/. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this document, which reflect management’s opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements. You are advised, however, to consult any additional disclosures we make in our reports to the SEC. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this document.
ii
PART I — FINANCIAL INFORMATION
MEDMEN ENTERPRISES INC.
Condensed Consolidated Balance Sheets (Unaudited)
As of September 24, 2022 and June 25, 2022
(Amounts Expressed in United States Dollars, Except for Share Data)
| September 24, | June 25, | |||||||
| 2022 | 2022 | |||||||
| (unaudited) | (audited) | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and Cash Equivalents | $ | $ | ||||||
| Accounts Receivable and Prepaid Expenses | ||||||||
| Inventory | ||||||||
| Assets Held for Sale | ||||||||
| Receivable for Assets Held for Sale | ||||||||
| Other Assets | ||||||||
| Total Current Assets | ||||||||
| Operating Lease Right-of-Use Assets | ||||||||
| Property and Equipment, Net | ||||||||
| Intangible Assets, Net | ||||||||
| Goodwill | ||||||||
| Other Non-Current Assets | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| LIABILITIES: | ||||||||
| Current Liabilities: | ||||||||
| Accounts Payable and Accrued Liabilities | $ | $ | ||||||
| Income Taxes Payable | ||||||||
| Other Liabilities | ||||||||
| Derivative Liabilities | ||||||||
| Current Portion of Operating Lease Liabilities | ||||||||
| Current Portion of Finance Lease Liabilities | ||||||||
| Current Portion of Notes Payable | ||||||||
| Liabilities Held for Sale | ||||||||
| Total Current Liabilities | ||||||||
| Operating Lease Liabilities | ||||||||
| Finance Lease Liabilities | ||||||||
| Other Non-Current Liabilities | ||||||||
| Deferred Tax Liability | ||||||||
| Senior Secured Convertible Credit Facility | ||||||||
| Notes Payable | ||||||||
| TOTAL LIABILITIES | ||||||||
| SHAREHOLDERS’ EQUITY: | ||||||||
| Preferred Shares ( par value, unlimited shares authorized and shares issued and outstanding) | ||||||||
| Subordinate Voting Shares (no par value, unlimited shares authorized, and shares issued and outstanding as of September 24, 2022 and June 26, 2022, respectively) | ||||||||
| Additional Paid-In Capital | ||||||||
| Accumulated Deficit | ( | ) | ( | ) | ||||
| Total Equity Attributable to Shareholders of MedMen Enterprises Inc. | ||||||||
| Non-Controlling Interest | ( | ) | ( | ) | ||||
| TOTAL SHAREHOLDERS’ EQUITY | ( | ) | ( | ) | ||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | $ | ||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).
1
MEDMEN ENTERPRISES INC.
Condensed Consolidated Statements of Operations (Unaudited)
Three Months Ended September 24, 2022 and September 25, 2021
(Amounts Expressed in United States Dollars, Except for Share Data)
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| Revenue | $ | $ | ||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses: | ||||||||
| General and Administrative | ||||||||
| Sales and Marketing | ||||||||
| Depreciation and Amortization | ||||||||
| Realized and Unrealized Changes in Fair Value of Contingent Consideration | ( | ) | ||||||
| Impairment Expense | ||||||||
| Other Operating (Income) Expense | ( | ) | ||||||
| Total Operating Expenses | ||||||||
| Loss from Operations | ( | ) | ( | ) | ||||
| Non-Operating (Income) Expenses: | ||||||||
| Interest Expense | ||||||||
| Interest Income | ( | ) | ( | ) | ||||
| Accretion of Debt Discount and Loan Origination Fees | ||||||||
| Change in Fair Value of Derivatives | ( | ) | ||||||
| Gain on Extinguishment of Debt | ( | ) | ||||||
| Total Non-Operating Expenses | ||||||||
| Loss from Continuing Operations Before Provision for Income Taxes | ( | ) | ( | ) | ||||
| Provision for Income Tax Expense | ( | ) | ( | ) | ||||
| Net Loss from Continuing Operations | ( | ) | ( | ) | ||||
| Net Income (Loss) from Discontinued Operations, Net of Taxes | ( | ) | ||||||
| Net Income (Loss) | ( | ) | ||||||
| Net Loss Attributable to Non-Controlling Interest | ( | ) | ( | ) | ||||
| Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc. | $ | $ | ( | ) | ||||
| Earnings (Loss) Per Share - Basic and Diluted: | ||||||||
| From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. | $ | ( | ) | $ | ( | ) | ||
| From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. | $ | $ | ( | ) | ||||
| Weighted-Average Shares Outstanding - Basic and Diluted | ||||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).
2
MEDMEN ENTERPRISES INC.
Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited)
Three Months Ended September 24, 2022 and September 25, 2021
(Amounts Expressed in United States Dollars, Except for Share Data)
| Units | $ Amount | TOTAL EQUITY ATTRIBUTABLE | ||||||||||||||||||||||||||
Subordinate Voting | Subordinate Voting Shares | Additional Paid-In Capital | Accumulated Deficit | TO SHAREHOLDERS OF MEDMEN | Non- Interest | TOTAL SHAREHOLDERS’ DEFICIENCY | ||||||||||||||||||||||
| BALANCE AS OF JUNE 26, 2022 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||
| Net Income (Loss) | - | ( | ) | |||||||||||||||||||||||||
| Controlling Interest Equity Transactions | ||||||||||||||||||||||||||||
| Partner Contributions | - | |||||||||||||||||||||||||||
| Redemption of MedMen Corp Redeemable Shares | ( | ) | ||||||||||||||||||||||||||
| Share-Based Compensation | - | |||||||||||||||||||||||||||
| BALANCE AS OF SEPTEMBER 24, 2022 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||
| Units | $ Amount | TOTAL EQUITY ATTRIBUTABLE | ||||||||||||||||||||||||||
Subordinate Voting | Subordinate Voting Shares | Additional Paid-In Capital | Accumulated Deficit | TO SHAREHOLDERS OF MEDMEN | Non- Interest | TOTAL SHAREHOLDERS’ DEFICIENCY | ||||||||||||||||||||||
| BALANCE AS OF JUNE 27, 2021 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||
| Net Loss | - | ( | ) | ( | ) | ( | ) | ( | ) | |||||||||||||||||||
| Controlling Interest Equity Transactions | ||||||||||||||||||||||||||||
| Shares Issued for Cash, Net of Fees | ||||||||||||||||||||||||||||
| Shares Issued to Settle Debt and Accrued Interest | ||||||||||||||||||||||||||||
| Shares Issued to Settle Accounts Payable and Liabilities | ||||||||||||||||||||||||||||
| Equity Component of Debt - New and Amended | - | |||||||||||||||||||||||||||
| Redemption of MedMen Corp Redeemable Shares | ( | ) | ||||||||||||||||||||||||||
| Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options | ||||||||||||||||||||||||||||
| Shares Issued for Exercise of Warrants | ||||||||||||||||||||||||||||
| Shares Issued for Conversion of Debt | ||||||||||||||||||||||||||||
| Stock Grants for Compensation | ||||||||||||||||||||||||||||
| Deferred Tax Impact On Conversion Feature | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||
| Share-Based Compensation | - | |||||||||||||||||||||||||||
| BALANCE AS OF SEPTEMBER 25, 2021 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).
3
MEDMEN ENTERPRISES INC.
Condensed Consolidated Statements of Cash Flows (Unaudited)
Three Months Ended September 24, 2022 and September 25, 2021
(Amounts Expressed in United States Dollars)
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net Loss from Continuing Operations | $ | ( | ) | $ | ( | ) | ||
| Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: | ||||||||
| Deferred Tax Expense | ( | ) | ||||||
| Depreciation and Amortization | ||||||||
| Non-Cash Operating Lease Costs | ||||||||
| Accretion of Debt Discount and Loan Origination Fees | ||||||||
| Loss on Disposals of Assets | ||||||||
| Gain on Lease Terminations | ( | ) | ||||||
| Accretion of Deferred Gain on Sale of Property | ( | ) | ( | ) | ||||
| Impairment of Assets | ||||||||
| Realized and Unrealized Changes in Fair Value of Contingent Consideration | ||||||||
| Change in Fair Value of Derivative Liabilities | ( | ) | ||||||
| Gain on Extinguishment of Debt | ( | ) | ||||||
| Share-Based Compensation | ||||||||
| Interest Capitalized to Senior Secured Convertible Debt and Notes Payable | ||||||||
| Interest Capitalized to Finance Lease Liabilities | ||||||||
| Changes in Operating Assets and Liabilities: | ||||||||
| Accounts Receivable and Prepaid Expenses | ||||||||
| Inventory | ( | ) | ||||||
| Other Current Assets | ||||||||
| Other Assets | ||||||||
| Accounts Payable and Accrued Liabilities | ( | ) | ||||||
| Interest Payments on Finance Leases | ( | ) | ( | ) | ||||
| Cash Payments - Operating Lease Liabilities | ( | ) | ( | ) | ||||
| Income Taxes Payable | ||||||||
| Other Current Liabilities | ( | ) | ( | ) | ||||
| Other Non-Current Liabilities | ||||||||
| NET CASH PROVIDED BY (USED IN) CONTINUED OPERATING ACTIVITIES | ( | ) | ||||||
| Net Cash Used in Discontinued Operating Activities | ( | ) | ( | ) | ||||
| NET CASH USED IN OPERATING ACTIVITIES | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of Property and Equipment | ( | ) | ||||||
| Additions to Intangible Assets | ( | ) | ( | ) | ||||
| Proceeds from the Sale of Assets Held for Sale | ||||||||
| Restricted Cash | ||||||||
| NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES | ( | ) | ||||||
| Net Cash Used in Discontinued Investing Activities | ( | ) | ||||||
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | ( | ) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Issuance of Subordinate Voting Shares for Cash | ||||||||
| Payment of Stock Issuance Costs Relating to Private Placement | ( | ) | ||||||
| Exercise of Warrants for Cash | ||||||||
| Payment of Debt Issuance Costs Relating to Senior Secured Convertible Credit Facility | ( | ) | ||||||
| Proceeds from Issuance of Notes Payable | ||||||||
| Principal Repayments of Notes Payable | ( | ) | ( | ) | ||||
| Principal Repayments of Finance Lease Liability | ( | ) | ( | ) | ||||
| Distributions - Non-Controlling Interest | ||||||||
| NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES | ( | ) | ||||||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | ||||||||
| Cash Included in Assets Held for Sale | ( | ) | ||||||
| Cash and Cash Equivalents, Beginning of Period | ||||||||
| CASH AND CASH EQUIVALENTS, END OF PERIOD | $ | $ | ||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).
4
MEDMEN ENTERPRISES INC.
Condensed Consolidated Statements of Cash Flows (Unaudited)
Three Months Ended September 24, 2022 and September 25, 2021
(Amounts Expressed in United States Dollars)
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION | ||||||||
| Cash Paid for Interest | $ | $ | ||||||
| Non-Cash Investing and Financing Activities: | ||||||||
| Net Assets Transferred to Held for Sale | $ | $ | ||||||
| Redemption of MedMen Corp Redeemable Shares | $ | $ | ||||||
| Derivative Liability Incurred on Convertible Facility and Equity Financing | $ | $ | ||||||
| Conversion of Convertible Debentures | $ | $ | ||||||
| Shares Issued to Settle Debt and Lender Fees | $ | $ | ||||||
| Shares Issued to Settle Accounts Payable and Liabilities | $ | $ | ||||||
| Equity Component of Debt - New and Amended | $ | $ | ||||||
| Deferred Tax Impact on Conversion Feature | $ | $ | ||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited).
5
MEDMEN ENTERPRISES INC.
Notes to Condensed Consolidated Financial Statements (Unaudited)
Three Months Ended September 24, 2022 and September 25, 2021
(Amounts Expressed in United States Dollars, Except for Share and Per Share Data)
| 1. | NATURE OF OPERATIONS |
MedMen Enterprises Inc. and its subsidiaries over which the company has control (collectively, “MedMen”, the “Company”, “we” or “us”) is a premier cannabis retailer based in the U.S. with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen offers a robust selection of high-quality products, including MedMen-owned brands – MedMen Red and LuxLyte – through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. MedMen Buds provides exclusive access to promotions, product drops and content.
As of September 24, 2022, the Company owns 23 store locations across California (13), Nevada (3), Illinois (1), Arizona (1), Massachusetts (1), and New York (4). The Company continues to market its assets in New York and thus classifies all assets and liabilities and profit or loss allocable to its operations in the state of New York as discontinued operations. In August 2022, the Company completed the sale of its operations in the state of Florida of which all assets and liabilities and profit or loss allocable to Florida are classified as discontinued operations until the day of sale, or August 22, 2022. As of September 24, 2022, the remaining post-acquisition assets and liabilities and profit or loss allocable to Florida have been reclassified as continuing operations.
6
| 2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Basis of Preparation
The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method.
In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.
The accompanying Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements have been condensed or omitted in accordance with SEC rules for interim financial information. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended June 25, 2022, as filed with the Securities and Exchange Commission on September 9, 2022 (the “2022 Form 10-K”).
Going Concern
As
of September 24, 2022, the Company had cash and cash equivalents of $
The Company plans to continue to fund its operations through the implementation of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with its master lease landlord and other landlords, divesture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue strategy of market expansion and retail revenue growth. The Company also needs to obtain an extension or a refinancing of its debt-in-default with the secured senior lender. The annual operating plan for fiscal year 2023 estimates the Company will be able to manage ongoing operations. However, its cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, management expects to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing.
7
COVID-19
In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. During the current reporting period, aspects of the Company’s business continue to be affected by impacts of the COVID-19 pandemic, as the Company’s retail stores strive to operate within the local rules and regulations of the states and localities in which the Company operates. While the Company saw continued recovery from the impacts of the COVID 19-pandemic during the first quarter of 2023, the Company continues to closely monitor the potential impact that a resurgence of the COVID-19 virus, including as a result of the emergence of new variants and strains, could have on the Company’s operations. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liabilities. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus.
Basis of Consolidation
Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company’s subsidiaries included in the Company’s 2022 Form 10-K remain complete as of September 24, 2022.
Significant Accounting Policies
The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in the Company’s 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended September 24, 2022.
The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued.
Reclassifications
Certain
amounts reported in the Notes to the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material
corrections and reclassified in order to conform to the current reporting period presentation. These non-material corrections and reclassifications
impacted leasehold improvements and furniture and fixtures in the amount of approximately $
8
Recently Adopted Accounting Standards
In May 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-04, “Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2021-04”), which amends existing guidance for earnings per share (“EPS”) in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements.
Recently Issued Accounting Standards
In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate (“LIBOR”) or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.
In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50)” (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.
9
| 3. | INVENTORY |
Inventory consists of the following:
| September 24, | June 25, | |||||||
| 2022 | 2022 | |||||||
| Raw Materials | $ | $ | ||||||
| Work-in-Process | ||||||||
| Finished Goods | ||||||||
| Total Inventory | $ | $ | ||||||
During
the three months ended September 24, 2022 and September 25, 2021, the Company recognized impairment of nil and $
10
| 4. | ASSETS HELD FOR SALE |
A reconciliation of our assets held for sale is as follows:
| Discontinued Operations (1) | Other Assets | TOTAL | ||||||||||
| Balance as of June 25, 2022 | $ | $ | $ | |||||||||
| Ongoing Activities | ( | ) | ( | ) | ||||||||
| Proceeds from Sale | ( | ) | ( | ) | ||||||||
| Gain on Sale of Assets Held for Sale | ||||||||||||
| Balance as of September 24, 2022 | $ | $ | $ | |||||||||
| (1) |
11
| 5. | PROPERTY AND EQUIPMENT |
As of September 24, 2022 and June 25, 2022, property and equipment consists of the following:
| September 24, | June 25, | |||||||
| 2022 | 2022 | |||||||
| Land and Buildings | $ | $ | ||||||
| Capital Leases | ||||||||
| Furniture and Fixtures | ||||||||
| Leasehold Improvements | ||||||||
| Equipment and Software | ||||||||
| Construction in Progress | ||||||||
| Total Property and Equipment | ||||||||
| Less Accumulated Depreciation | ( | ) | ( | ) | ||||
| Property and Equipment, Net | $ | $ | ||||||
Depreciation
expense related to continuing operations of $
Borrowing
costs were not capitalized as there were no active construction projects in progress during the three months ended September 24,
2022. During the three months ended September 25, 2021, borrowing costs totaling $
12
| 6. | INTANGIBLE ASSETS |
As of September 24, 2022 and June 25, 2022, intangible assets consist of the following:
| September 24, | June 25, | |||||||
| 2022 | 2022 | |||||||
| Dispensary Licenses | $ | $ | ||||||
| Customer Relationships | ||||||||
| Capitalized Software | ||||||||
| Intellectual Property | ||||||||
| Total Intangible Assets | ||||||||
| Dispensary Licenses | ( | ) | ( | ) | ||||
| Customer Relationships | ( | ) | ( | ) | ||||
| Capitalized Software | ( | ) | ( | ) | ||||
| Intellectual Property | ( | ) | ( | ) | ||||
| Less Accumulated Amortization | ( | ) | ( | ) | ||||
| Intangible Assets, Net | $ | $ | ||||||
The
Company recorded amortization expense related to continuing operations of $
13
| 7. | ACCOUNTS PAYABLE AND ACCRUED LIABILITIES |
As of September 24, 2022 and June 25, 2022, accounts payable and accrued liabilities consist of the following:
| September 24, | June 25, | |||||||
| 2022 | 2022 | |||||||
| Accounts Payable | $ | $ | ||||||
| Accrued Liabilities | ||||||||
| Accrued Inventory | ||||||||
| Accrued Payroll | ||||||||
| Local & State Taxes Payable | ||||||||
| Total Accounts Payable and Accrued Liabilities | $ | $ | ||||||
14
| 8. | DERIVATIVE LIABILITIES |
A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the three months ended September 24, 2022 is as follows:
| September 24, | ||||
| 2022 | ||||
| Balance at Beginning of Period | $ | |||
| Change in Fair Value of Derivative Liabilities | ||||
| Balance at End of Period | $ | |||
On August 17, 2021, in connection with the amended and restated senior secured convertible credit facility (the Sixth Amendment”), the Company provided the note holders top-up and preemptive rights which were bifurcated from the related notes and classified as a derivative due to the variability of the number and price of shares issuable under these rights. See “Note 11 – Senior Secured Convertible Credit Facility” for further information.
The fair value of the top-up provision in connection with Sixth Amendment of the Convertible Facility was determined using the Black Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used at September 24, 2022:
| Top-Up Provision | ||||
| Average Stock Price | $ | |||
| Weighted-Average Probability | % | |||
| Term (in Years) | ||||
| Expected Stock Price Volatility | % | |||
The following are the warrants issued related to the equity financing transactions that were accounted for as derivative liabilities:
| Number
of Warrants | Exercise Price | Expiration Date |
||||||||
| March 2021 Private Placement (1) | C$0.50 | March 27, 2024 | ||||||||
| (1) |
The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables:
| Expected Stock Price Volatility | % | |||
| Risk-Free Annual Interest Rate | % | |||
| Expected Life (in Years) | ||||
| Share Price | $ | |||
| Exercise Price | $ |
15
| 9. | LEASES |
The Company has various operating and finance leases for land, buildings, equipment and other assets that are used for corporate purposes as well as for the production and sale of cannabis products. These leases are subject to covenants and restrictions standard to the industry in which the Company operates.
The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three months ended September 24, 2022 and September 25, 2021:
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| Finance Lease Cost: | ||||||||
| Amortization of Finance Lease Right-of-Use Assets | $ | $ | ||||||
| Interest on Lease Liabilities | ||||||||
| Operating Lease Cost | ||||||||
| Sublease Income (1) | ( | ) | ||||||
| Total Lease Expenses | $ | $ | ||||||
| Cash Paid for Amounts Included in the Measurement of Lease Liabilities: | ||||||||
| Financing Cash Flows from Finance Leases | $ | $ | ||||||
| Operating Cash Flows from Operating Leases | $ | $ | ||||||
| (1) |
The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of September 24, 2022 and June 25, 2022, is as follows:
| September 24, | June 25, | |||||||
| 2022 | 2022 | |||||||
| Weighted-Average Remaining Lease Term (Years) - Finance Leases | ||||||||
| Weighted-Average Remaining Lease Term (Years) - Operating Leases | ||||||||
| Weighted-Average Discount Rate - Finance Leases | % | % | ||||||
| Weighted-Average Discount Rate - Operating Leases | % | % | ||||||
16
Future lease payments under non-cancellable operating leases and finance leases as of September 24, 2022 are as follows:
| Fiscal Year Ending | Operating Leases | Finance Leases | ||||||
| July 1, 2023 (remaining) | $ | $ | ||||||
| June 29, 2024 | ||||||||
| June 28, 2025 | ||||||||
| June 27, 2026 | ||||||||
| June 26, 2027 | ||||||||
| Thereafter | ||||||||
| Total Lease Payments | ||||||||
| Less Interest | ( | ) | ( | ) | ||||
| Lease Liability Recognized | $ | $ | ||||||
The Company entered into a management agreement (the “Management Agreement”) with a third party to operate its cultivation facilities in California and Nevada (the “Cultivation Facilities”). On September 30, 2021, the landlord approved the third party to operate the leased facilities which effectuated the Management Agreement. The Management Agreement provides the third party an option to acquire all the assets used in the Cultivation Facilities, including the cannabis licenses and equipment, for $1 (the “Purchase Option”). The fee for the services under the Management Agreement is 100% and 30% of the California and Nevada Cultivation Facilities net revenue, respectively. The term of the Management Agreement remains in effect until the earlier of (a) the closing of any sale pursuant to the Purchase Option and (b) the expiration of the term, as applicable, of the master lease, at which time this Management Agreement shall automatically terminate without any further action of the Parties. As of September 24, 2022, the Management Agreement remains in effect as neither termination condition has occurred. During the three months ended September 24, 2022, the Company recorded sublease income under the Management Agreement. See “Note 16 – Other Operating Income” for further information.
17
| 10. | NOTES PAYABLE |
Refer to the 2022 Form 10-K for complete disclosure of current terms of notes payable included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended September 24, 2022.
As of September 24, 2022 and June 25, 2022, notes payable consist of the following:
| September 24, | June 25, | |||||||
| 2022 | 2022 | |||||||
| Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. | $ | $ | ||||||
| Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. | ||||||||
| Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471. | ||||||||
| Other | ||||||||
| Total Notes Payable | ||||||||
| Less Unamortized Debt Issuance Costs and Loan Origination Fees | ( | ) | ||||||
| Net Amount | $ | $ | ||||||
| Less Current Portion of Notes Payable | ( | ) | ( | ) | ||||
| Notes Payable, Net of Current Portion | $ | $ | ||||||
18
A reconciliation of the beginning and ending balances of notes payable for the three months ended September 24, 2022 is as follows:
| September 24, | ||||
| 2022 | ||||
| Balance at Beginning of Period | $ | |||
| Paid-In-Kind Interest Capitalized | ||||
| Cash Payments | ( | ) | ||
| Accretion of Debt Discount Included in Discontinued Operations | ||||
| Balance at End of Period | ||||
| Less Current Portion of Notes Payable | ( | ) | ||
| Notes Payable, Net of Current Portion | $ | |||
Non-Revolving Senior Secured Term Loan Facility
In
February 2022, the Company executed the Sixth Modification extending the maturity date of the senior secured term loan facility
(the “Facility”) with Hankey Capital and Stable Road Capital (the “Lenders”) to July 31, 2022 with respect
to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the “Term Loans”). The
Sixth Modification required that the Company make a mandatory prepayment of at least $
During
the three months ended September 24, 2022, in connection with the sale of the Company’s Florida-based operations, the Company
made a principal repayment of $
19
| 11. | SENIOR SECURED CONVERTIBLE CREDIT FACILITY |
Refer to the 2022 Form 10-K for complete disclosure of current terms of the senior secured convertible facility included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended September 24, 2022.
As of September 24, 2022 and June 25, 2022, senior secured convertible credit facility consists of the following:
| September 24, | June 25, | |||||||||
| Tranche | 2022 | 2022 | ||||||||
| Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 1A | $ | $ | |||||||
| Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 1B | |||||||||
| Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 2 | |||||||||
| Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 3 | |||||||||
| Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | 4 | |||||||||
| Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | - | |||||||||
| Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | IA-1 | |||||||||
| Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | IA-2 | |||||||||
| Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | - | |||||||||
| Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | - | |||||||||
| Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. | - | |||||||||
| Total Drawn on Senior Secured Convertible Credit Facility | ||||||||||
| Less Unamortized Debt Discount | ( | ) | ( | ) | ||||||
| Senior Secured Convertible Credit Facility, Net | $ | $ | ||||||||
20
A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the three months ended September 24, 2022 is as follows:
| Tranche 1 | Tranche 2 | Tranche 3 | Tranche 4 | Incremental Advance - 1 | Incremental Advance - 2 | 3rd Advance | Amendment
Fee Notes | Restatement Fee Notes | 2nd Restatement Fee Notes | TOTAL | ||||||||||||||||||||||||||||||||||
| Balance as of June 25, 2022 | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||
| Paid-In-Kind Interest Capitalized | ||||||||||||||||||||||||||||||||||||||||||||
| Accretion of Debt Discount | ||||||||||||||||||||||||||||||||||||||||||||
| Balance as of September 24, 2022 | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||
21
| 12. | SHAREHOLDERS’ EQUITY |
Issued and Outstanding
A reconciliation of the beginning and ending issued and outstanding shares is as follows:
| Subordinate Voting Shares | MM
CAN USA Class B Redeemable Units | MM
Enterprises USA Common Units | ||||||||||
| Balance as of June 25, 2022 | ||||||||||||
| Redemption of MedMen Corp Redeemable Shares | ( | ) | ||||||||||
| Balance as of September 24, 2022 | ||||||||||||
Non-Controlling Interests
Non-controlling
interest represents the net assets of the subsidiaries that the holders of the Subordinate Voting Shares do not directly own. The net
assets of the non-controlling interest are represented by the holders of MM CAN USA Redeemable Shares and the holders of MM Enterprises
USA Common Units. Non-controlling interest also represents the net assets of the entities the Company does not directly own but controls
through a management agreement. As of September 24, 2022 and June 25, 2022, the holders of the MM CAN USA Redeemable Shares
represent approximately
Variable Interest Entities
The below information are entities the Company has concluded to be variable interest entities (“VIEs”) as the Company possesses the power to direct activities through management services agreements (“MSAs”). Through these MSAs, the Company can significantly impact the VIEs and thus holds a controlling financial interest. The following table represents the summarized financial information about the Company’s consolidated VIEs. VIEs include the balances of Venice Caregiver Foundation, Inc., LAX Fund II Group, LLC, and Natures Cure, Inc. This information represents amounts before intercompany eliminations.
As of and for the three months ended September 24, 2022, the balances and activities attributable to the VIEs consist of the following:
| Venice Caregivers Foundation, Inc. | LAX Fund II Group, LLC | Natures Cure, Inc. | TOTAL | |||||||||||||
| Current Assets | $ | $ | $ | $ | ||||||||||||
| Non-Current Assets | ||||||||||||||||
| Total Assets | $ | $ | $ | $ | ||||||||||||
| Current Liabilities | $ | $ | $ | $ | ||||||||||||
| Non-Current Liabilities | ||||||||||||||||
| Total Liabilities | $ | $ | $ | $ | ||||||||||||
| Non-Controlling Interest | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||
| Revenues | $ | $ | $ | $ | ||||||||||||
| Net (Loss) Income Attributable to Non-Controlling Interest | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||
22
As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following:
| Venice Caregivers Foundation, Inc. | LAX Fund II Group, LLC | Natures Cure, Inc. | TOTAL | |||||||||||||
| Current Assets | $ | $ | $ | $ | ||||||||||||
| Non-Current Assets | ||||||||||||||||
| Total Assets | $ | $ | $ | $ | ||||||||||||
| Current Liabilities | $ | $ | $ | $ | ||||||||||||
| Non-Current Liabilities | ||||||||||||||||
| Total Liabilities | $ | $ | $ | $ | ||||||||||||
| Non-Controlling Interest | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||
| Revenues | $ | $ | $ | $ | ||||||||||||
| Net (Loss) Income Attributable to Non-Controlling Interest | $ | ( | ) | $ | ( | ) | $ | $ | ||||||||
The net change in the consolidated VIEs and other non-controlling interest are as follows for the three months ended September 24, 2022:
| Venice Caregivers Foundation, Inc. | LAX Fund II Group, LLC | Natures Cure, Inc. | Other Non- Controlling Interests | TOTAL | ||||||||||||||||
| Balance as of June 25, 2022 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||
| Net (Loss) Income | ( | ) | ( | ) | ( | ) | ||||||||||||||
| Balance as of September 24, 2022 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||
Le Cirque Rouge, LP (the “OP”) is a Delaware limited partnership that holds substantially all of the real estate assets owned by the Treehouse Real Estate Investment Trust (the “REIT”), conducts the REIT’s operations and is financed by the REIT. Under Accounting Standards Codification (“ASC”) Topic 810, “Consolidation” (“ASC Topic 810”), the OP was determined to be a variable interest entity in which the Company has an implicit variable interest based on the leasing relationship and arrangement with the REIT. However, the Company is not the primary beneficiary under ASC Topic 810. Accordingly, Le Cirque Rouge, LP is not consolidated as a variable interest entity within the Consolidated Financial Statements. As of and during the three months ended September 24, 2022, the Company continues to have a variable interest in the OP and did not provide any financial or other support to the REIT other than the completion of the sale and leaseback transactions and the REIT being a lessor on various leases as described in “Note 9 – Leases”.
23
| 13. | SHARE-BASED COMPENSATION |
The Company has a stock and equity incentive plan (the “Incentive Plan”) under which the Company may issue various types of equity instruments to any employee, officer, consultant, advisor or director. The types of equity instruments issuable under the Incentive Plan encompass, among other things, stock options, stock grants, and restricted stock units (together, “Awards”). Stock based compensation expenses are recorded as a component of general and administrative expenses. The maximum number of Awards that may be issued under the Incentive Plan shall be determined by the Compensation Committee or the Board of Directors in the absence of a Compensation Committee. Any shares subject to an Award under the Incentive Plan that are forfeited, cancelled, expire unexercised, are settled in cash or are used or withheld to satisfy tax withholding obligations, shall again be available for Awards under the Incentive Plan. Vesting of Awards will be determined by the Compensation Committee or Board of Directors in absence of a Compensation Committee. The exercise price for Awards (if applicable) will generally not be less than the fair market value of the Award at the time of grant and will generally expire after or years.
A summary of share-based compensation expense for the three months ended September 24, 2022 and September 25, 2021 is as follows:
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| Stock Options | $ | $ | ||||||
| Stock Grants for Compensation | ||||||||
| Restricted Stock Grants | ||||||||
| Total Share-Based Compensation | $ | $ | ||||||
Stock Options
A reconciliation of the beginning and ending balance of stock options outstanding is as follows:
| Number
of Stock Options | Weighted-Average Exercise Price | |||||||
| Balance as of June 25, 2022 | $ | |||||||
| Forfeited and Expired | ( | ) | $ | ( | ) | |||
| Balance as of September 24, 2022 | $ | |||||||
| Stock Options Exercisable as of September 24, 2022 | $ | |||||||
24
Long-Term Incentive Plan (“LTIP”) Units and LLC Redeemable Units
A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows:
| Weighted | |||||||||||||
| LTIP Units | LLC | Average | |||||||||||
| Issued and | Redeemable | Grant Date | |||||||||||
| Outstanding | Units | Fair Value | |||||||||||
| Balance as of June 25, 2022 and September 24, 2022 | $ | ||||||||||||
Restricted Stock Units
A reconciliation of the beginning and ending balance of restricted stock units outstanding is as follows:
| Issued
and Outstanding | Vested (1) | Weighted-Average Fair Value | ||||||||||
| Balance as of June 25, 2022 | $ | |||||||||||
| Forfeiture of Restricted Stock (2) | ( | ) | $ | ( | ) | |||||||
| Vesting of Restricted Stock | $ | |||||||||||
| Balance as of September 24, 2022 | $ | |||||||||||
| (1) |
| (2) |
Warrants
A reconciliation of the beginning and ending balance of warrants outstanding is as follows:
| Number of Warrants Outstanding | |||||||||||||||||
| Subordinate Voting Shares | MM
CAN USA Redeemable Shares | TOTAL | Weighted-Average Exercise Price | ||||||||||||||
| Balance as of June 25, 2022 | $ | ||||||||||||||||
| Expired | ( | ) | ( | ) | $ | ( | ) | ||||||||||
| Balance as of September 24, 2022 | $ | ||||||||||||||||
25
| 14. | LOSS PER SHARE |
The following is a reconciliation for the calculation of basic and diluted loss per share for the three months ended September 24, 2022 and September 25, 2021:
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. | $ | ( | ) | $ | ( | ) | ||
| Net Income (Loss) from Discontinued Operations | ( | ) | ||||||
| Total Net Income (Loss) | $ | $ | ( | ) | ||||
| Weighted-Average Shares Outstanding - Basic and Diluted | ||||||||
| Earnings (Loss) Per Share - Basic and Diluted: | ||||||||
| From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. | $ | ( | ) | $ | ( | ) | ||
| From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. | $ | $ | ( | ) | ||||
Diluted loss per share is the same as basic loss per share as the issuance of shares on the exercise of convertible debentures, LTIP share units, warrants and share options is anti-dilutive.
26
| 15. | GENERAL AND ADMINISTRATIVE EXPENSES |
During the three months ended September 24, 2022 and September 25, 2021, general and administrative expenses consisted of the following:
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| Salaries and Benefits | $ | $ | ||||||
| Professional Fees | ||||||||
| Rent | ||||||||
| Licenses, Fees and Taxes | ||||||||
| Share-Based Compensation | ||||||||
| Deal Costs | ||||||||
| Other General and Administrative | ||||||||
| Total General and Administrative Expenses | $ | $ | ||||||
27
| 16. | OTHER OPERATING (INCOME) EXPENSE |
During the three months ended September 24, 2022 and September 25, 2021, other operating (income) expense consisted of the following:
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| Loss on Disposals of Assets | $ | $ | ||||||
| Restructuring and Reorganization Expense | ||||||||
| Gain on Settlement of Accounts Payable | ( | ) | ( | ) | ||||
| Gain on Lease Terminations | ( | ) | ||||||
| Other Income | ( | ) | ( | ) | ||||
| Total Other Operating (Income) Expense | $ | ( | ) | $ | ||||
During
the three months ended September 24, 2022, the Company recorded $
28
| 17. | PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES |
The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended September 24, 2022 and September 25, 2021:
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| Loss from Continuing Operations Before Provision for Income Taxes | $ | ( | ) | $ | ( | ) | ||
| Income Tax Expense | ( | ) | ( | ) | ||||
| Effective Tax Rate | - | % | - | % | ||||
We have historically calculated the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate (“AETR”) for the full fiscal year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. For the three months ended September 25, 2021, we determined we could no longer reliably estimate income taxes utilizing an AETR. The AETR estimate is highly sensitive to estimates of ordinary income (loss) and permanent differences such that minor fluctuations in these estimates could result in significant fluctuations of the Company’s AETR. Accordingly, we used our actual year-to-date effective tax rate to calculate income taxes for the three months ended September 25, 2022.
As the Company operates in the legal cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal, Illinois state, Massachusetts state and New York state income tax purposes under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, the State of California does not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its California Franchise Tax Returns.
The effective tax rate for the three months ended September 24, 2022 is different from the three months ended September 25, 2021, respectively, primarily due to the Company’s income and related 280E expenditures. The Company’s non-deductible expenses related to IRC Section 280E limitations have remained relatively consistent.
The
Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and in Canada. The Company is generally
subject to audit by taxing authorities in various U.S., state, and in foreign jurisdictions for fiscal years 2014 through the current
fiscal year. As of September 24, 2022, the Company had $
29
| 18. | COMMITMENTS AND CONTINGENCIES |
Contingencies
The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of these regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulations as of September 24, 2022 and June 25, 2022, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future.
Claims and Litigation
From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 24, 2022, there were no pending or threatening lawsuits that could be reasonably assessed to have resulted in a probable loss to the Company in an amount that can be reasonably estimated. As such, no accrual has been made in the Condensed Consolidated Financial Statements relating to claims and litigations. As of September 24, 2022, there are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest.
In March 2020, litigation was filed against the Company in the Superior Court of Arizona, Maricopa County, related to a purchase agreement for a previous acquisition. The Superior Court of Arizona, Maricopa County granted summary judgement in favor of the Company on all counts in July 2022. The Company is currently in process of recovering certain fees and costs associated with the lawsuit from the plaintiffs. The Company believes the likelihood of a loss contingency is neither probable nor estimable. As such, no amount has been accrued in these financial statements.
In April 2020, a complaint was filed against the Company in Los Angeles Superior Court related to a contemplated acquisition in which the plaintiffs are seeking damages for alleged breach of contract and breach of implied covenant of good faith and fair dealing seeking declaratory relief and specific performance. The Company has filed counterclaims including for breach of contract, breach of promissory note, unjust enrichment and declaratory relief. The Company believes the likelihood of a loss contingency is remote. As such, no amount has been accrued in the financial statements.
In May 2020, litigation was filed against the Company related to a purchase agreement and secured promissory note for a previous acquisition. The Company is currently defending against this lawsuit, which claims for breach of contract, breach of implied covenant of good faith and fair dealing, common law fraud and securities fraud. The plaintiffs are seeking damages for such claims in which the amount is currently not reasonably estimable. In response, the Company filed a counterclaim and is seeking entitlement to proceeds of the sale, net of amounts owed under the secured promissory note. The plaintiffs filed an appeal to the ruling on the entitlement of proceeds in excess of the secured promissory note which was dismissed. The additionally claims and counterclaims are currently in dispute. Any loss recoveries related to the Company’s counterclaim have not been recorded. In addition, net proceeds resulting from the sale was not recognized as a receivable as the amount is not reasonably estimable.
In September 2020 and May 2020, legal disputes were filed against the Company related to the separation of former officers in which the severance issued is currently being disputed. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements.
30
In November 2020, entities affiliated with former officers of the Company initiated arbitration against a subsidiary of the Company in Los Angeles, California asserting breach of contract, breach of the implied covenant of good faith and fair dealing, fraud, and unjust enrichment. The claimants are generally seeking damages and compensatory damages according to proof, including lost earnings and other benefits, past and future, interest on lost earnings and benefits, reasonable attorney’s fees, and such other and further relief as the court deems proper. The Company asserted counterclaims, including for breach of the same management agreements. The arbitration is currently set for hearing in December 2022. The litigation is at an early stage and the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements.
In October 2021, a suit for premises liability and negligence seeking unspecified damages for pain and suffering, disability, mental and emotional distress, and loss of earnings was filed against the Company in Los Angeles Superior Court. The matter is in the process of being litigated. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements.
The Company is the defendant in several complaints filed by various of its landlords seeking rents and damages under leases. In 2020 a complaint was filed in Cook County Circuit Court, Illinois against the Company by a landlord claiming the Company had failed to meet its obligations to apply effort to obtain a retail cannabis license at a property and seeking rents and damages. The litigation is currently in the discovery phase. If the litigation is not settled or resolved, trial will likely take place During the fiscal year ended 2023. In July 2022, a complaint was filed against the Company in the United States District Court for the Southern District of New York by a landlord seeking damages under a lease on real estate located in Illinois. The Company is required to file an answer to the complaint by September 2022. Prior attempts to resolve the lease dispute with this landlord have failed. In June 2022, a complaint was filed against the Company by the Company’s landlord at its cultivation center in Utica, New York, related to an agreement to purchase land next to the cultivation center, which land was also owned by the landlord. Plaintiff seeks to enforce a land purchase agreement and seeks damages. In April 2022, the landlord at the Company’s dispensary location in Tampa, Florida, filed suit seeking damages under a lease, shortly after the Company announced its plans to sell its Florida business. The Company retained this lease and litigation following the sale of the Florida business and the litigation is at an early stage and the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements.
31
| 19. | RELATED PARTY TRANSACTIONS |
The
Company’s Board of Directors each receive quarterly fees of $
32
| 20. | SEGMENT INFORMATION |
The Company currently operates in one segment, the production and sale of cannabis products, which is how the Company’s Chief Operating Decision Maker manages the business and makes operating decisions. The Company’s cultivation operations are not considered significant to the overall operations of the Company. Intercompany sales and transactions are eliminated in consolidation.
33
| 21. | REVENUE |
While the Company operates in one segment as disclosed in “Note 20 – Segment Information”, the Company is disaggregating its revenue by geographical region in accordance with ASC 606, “Revenue from Contracts with Customers”. Revenue by state for the periods presented are as follows:
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| California | $ | $ | ||||||
| Nevada | ||||||||
| Illinois | ||||||||
| Arizona | ||||||||
| Massachusetts | ||||||||
| Revenue from Continuing Operations | $ | $ | ||||||
| Revenue from Discontinued Operations | ||||||||
| Total Revenue | $ | $ | ||||||
34
| 22. | DISCONTINUED OPERATIONS |
On February 28, 2022, MME Florida LLC and its parent, MM Enterprises USA, LLC, a wholly-owned subsidiary of the Company entered into an Asset Purchase Agreement (the “Agreement”) with Green Sentry Holdings, LLC, (“Buyer”) for the sale of substantially all of the Company’s Florida-based assets, including its license, dispensaries, inventory and cultivation operations, and assumption of certain liabilities.
On
August 22, 2022, the Company closed the transaction at the final sales price of $
The operating results of the discontinued operations are summarized as follows:
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| 2022 | 2021 | |||||||
| Revenue | $ | $ | ||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Expenses: | ||||||||
| General and Administrative | ||||||||
| Sales and Marketing | ||||||||
| Depreciation and Amortization | ||||||||
| Impairment Expense | ( | ) | ||||||
| Gain on Disposal of Assets and Other Income | ( | ) | ( | ) | ||||
| Total (Income) Expenses | ( | ) | ||||||
| Income (Loss) from Discontinued Operations | ( | ) | ||||||
| Other Expense: | ||||||||
| Interest Expense | ||||||||
| Accretion of Debt Discount and Loan Origination Fees | ||||||||
| Total Other Expense | ||||||||
| Income (Loss) from Discontinued Operations Before Provision for Income Taxes | ( | ) | ||||||
| Provision for Income Tax Benefit (Expense) | ( | ) | ( | ) | ||||
| Net Income (Loss) from Discontinued Operations | $ | $ | ( | ) | ||||
35
The carrying amounts of assets and liabilities in the disposal group are summarized as follows:
| September 24, | June 25, | |||||||
| 2022 | 2022 | |||||||
| Carrying Amounts of the Assets Included in Discontinued Operations: | ||||||||
| Cash and Cash Equivalents | $ | $ | ||||||
| Restricted Cash | ||||||||
| Accounts Receivable and Prepaid Expenses | ||||||||
| Inventory | ||||||||
| TOTAL CURRENT ASSETS (1) | ||||||||
| Property and Equipment, Net | ||||||||
| Operating Lease Right-of-Use Assets | ||||||||
| Intangible Assets, Net | ||||||||
| Other Assets | ||||||||
| TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE | $ | $ | ||||||
| Carrying Amounts of the Liabilities Included in Discontinued Operations: | ||||||||
| Accounts Payable and Accrued Liabilities | $ | $ | ||||||
| Income Taxes Payable | ( | ) | ||||||
| Other Current Liabilities | ||||||||
| Current Portion of Operating Lease Liabilities | ||||||||
| Current Portion of Finance Lease Liabilities | ||||||||
| TOTAL CURRENT LIABILITIES (1) | ||||||||
| Operating Lease Liabilities, Net of Current Portion | ||||||||
| Deferred Tax Liabilities | ||||||||
| Notes Payable | ||||||||
| TOTAL NON-CURRENT LIABILITIES (1) | ||||||||
| TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE | $ | $ | ||||||
36
| 23. | SUBSEQUENT EVENTS |
The Company has evaluated subsequent events through the date these Condensed Consolidated Financial Statements were issued and has concluded that no subsequent events have occurred that would require recognition in the Condensed Consolidated Financial Statements or disclosure in the Notes to the Condensed Consolidated Financial Statements.
37
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
This management’s discussion and analysis (“MD&A”) of the financial condition and results of operations of MedMen Enterprises Inc. (“MedMen Enterprises”, “MedMen”, the “Company”, “we” or “our”) is for the three months ended September 24, 2022. The following discussion should be read in conjunction with, and is qualified in its entirety by, the Condensed Consolidated Financial Statements and the accompanying notes presented in Item 1 of this Form 10-Q and those discussed in Item 8 of the Company’s Annual Report on Form 10-K (the “Form 10-K”) filed with the SEC on September 9, 2022. Except for historical information, the discussion in this section contains forward-looking statements that involve risks and uncertainties. Future results could differ materially from those discussed below for many reasons, including the risks described in “Disclosure Regarding Forward-Looking Statements,” Item 1A. “Risk Factors” and elsewhere in this Form 10-Q.
We are a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act. Accordingly, we have omitted certain information called for by this Item as permitted by applicable scaled disclosure rules.
All references to “$” and “dollars” refer to U.S. dollars. References to C$ refer to Canadian dollars. Certain totals, subtotals and percentages throughout this MD&A may not reconcile due to rounding.
Our fiscal year is a 52/53-week year ending on the last Saturday in June or first Saturday in July. For the current interim period, the three months ended September 24, 2022 and September 25, 2021 refer to the 13 weeks ended therein.
Overview
MedMen is a cannabis retailer based in the U.S. offering a robust selection of high-quality products, including MedMen-owned brands, LuxLyte, and MedMen Red through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. As of September 24, 2022, the Company operates 23 store locations across California (13), New York (4) Nevada (3), Illinois (1), Massachusetts (1) and Arizona (1).
On August 22, 2022, the Company completed the sale of its operations in the state of Florida, including its license, dispensaries, inventory and cultivation operations, to Green Sentry Holdings, LLC (“Buyer”) at the final sales price of $67,000,000 which comprised of $63,000,000 in cash and $4,000,000 in liabilities assumed by the Buyer. The Buyer made a cash payment of $40,000,000 at closing, a cash payment of $11,500,000 on September 15, 2022, and is required to make one additional installment payments of $11,500,000 on or before March 15, 2023. As of September 24, 2022, net proceeds to the Company were $19,500,000 after $31,599,999 of the cash proceeds was used to repay the Senior Secured Term Loans with Hankey Capital. Proceeds of the transaction to the Company will be used to fund operations and pay interest to Hankey Capital while the Senior Secured Term Loans remain outstanding and in default. In addition, the Company licensed the tradename “MedMen” to the Buyer for use in Florida for a period of two years, subject to termination rights, for a quarterly revenue-based fee. All purchased assets and assumed liabilities related to Florida are excluded from our Consolidated Balance Sheets as of September 24, 2022 and all profits or losses from our Florida operations subsequent to August 22, 2022 are included in the Consolidated Statements of Operations. Refer to “Note 22 – Discontinued Operations” of the Consolidated Financial Statements in Item 1 for further information.
COVID-19 Pandemic
We continuously address the effects of the COVID-19 pandemic, a discussion of which is available in Item 1A “Risk Factors” of the 2022 Form 10-K. Our business and operating results for the three months ended September 24, 2022, continue to be impacted by the COVID-19 pandemic. The overall impact on our business continues to depend on the length of time that the pandemic continues, the impact on consumer purchasing behavior, inflation, and the extent to which it affects our ability to raise capital, and the effect of governmental regulations imposed in response to the pandemic, which all remain uncertain at this time. We continue to implement and evaluate actions to strengthen our financial position and support the continuity of our business and operations.
38
Results of Operations
Our consolidated results, in millions, except for per share and percentage data, for the three months ended September 24, 2022, compared to three months ended September 25, 2021, are as follows:
| Three Months Ended | ||||||||||||||||
| September 24, | September 25, | |||||||||||||||
| ($ in Millions) | 2022 | 2021 | $ Change | % Change | ||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Revenue | $ | 30.0 | $ | 36.7 | $ | (6.7 | ) | (18 | %) | |||||||
| Cost of Goods Sold | 15.2 | 19.3 | (4.1 | ) | (21 | %) | ||||||||||
| Gross Profit | 14.9 | 17.4 | (2.5 | ) | (14 | %) | ||||||||||
| Operating Expenses: | ||||||||||||||||
| General and Administrative | 17.8 | 32.6 | (14.8 | ) | (45 | %) | ||||||||||
| Sales and Marketing | 0.4 | 0.6 | (0.2 | ) | (33 | %) | ||||||||||
| Depreciation and Amortization | 3.9 | 5.8 | (1.9 | ) | (33 | %) | ||||||||||
| Unrealized Changes in Fair Value of Contingent Consideration | (0.9 | ) | - | (0.9 | ) | - | ||||||||||
| Impairment Expense | 1.7 | 0.4 | 1.3 | 325 | % | |||||||||||
| Other Operating (Income) Expense | (2.6 | ) | 2.2 | (4.8 | ) | (218 | %) | |||||||||
| Total Operating Expenses | 20.5 | 41.7 | (21.3 | ) | (51 | %) | ||||||||||
| Loss from Operations | (5.6 | ) | (24.3 | ) | 18.7 | (77 | %) | |||||||||
| Non-Operating Expense (Income): | ||||||||||||||||
| Interest Expense | 10.1 | 8.2 | 1.9 | 23 | % | |||||||||||
| Accretion of Debt Discount and Loan Origination Fees | 1.6 | 6.3 | (4.7 | ) | (75 | %) | ||||||||||
| Change in Fair Value of Derivatives | 0.8 | (2.1 | ) | 2.9 | (138 | %) | ||||||||||
| Gain on Extinguishment of Debt | - | (10.2 | ) | 10.2 | (100 | %) | ||||||||||
| Total Non-Operating Expense | 12.4 | 2.2 | 10.2 | 464 | % | |||||||||||
| Loss from Continuing Operations Before Provision for Income Taxes | (18.1 | ) | (26.5 | ) | 8.4 | (32 | %) | |||||||||
| Provision for Income Tax Expense | (2.2 | ) | (19.7 | ) | 17.5 | (89 | %) | |||||||||
| Net Loss from Continuing Operations | (20.3 | ) | (46.2 | ) | 25.9 | (56 | %) | |||||||||
| Net Income (Loss) from Discontinued Operations, Net of Taxes | 24.3 | (14.4 | ) | 38.7 | (269 | %) | ||||||||||
| Net Income (Loss) | 4.0 | (60.6 | ) | 64.6 | (107 | %) | ||||||||||
| Net Loss Attributable to Non-Controlling Interest | (0.1 | ) | (5.3 | ) | 5.2 | (98 | %) | |||||||||
| Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc. | $ | 4.2 | $ | (55.3 | ) | $ | 59.5 | (108 | %) | |||||||
| EBITDA from Continuing Operations (Non-GAAP) | $ | (2.5 | ) | $ | (5.7 | ) | $ | 3.2 | (56 | %) | ||||||
| Adjusted EBITDA from Continuing Operations (Non-GAAP) | $ | (2.0 | ) | $ | (12.2 | ) | $ | 10.2 | (84 | %) | ||||||
39
Revenue
Revenue for the three months ended September 24, 2022 was $30.0 million, a decrease of $(6.7) million, or (18%), compared to revenue of $36.7 million for the three months ended September 25, 2021.
Revenue in various states in which we operate is as follows:
| Three Months Ended | ||||||||||||||||
| September 24, | September 25, | |||||||||||||||
| ($ in Millions) | 2022 | 2021 | $ Change | % Change | ||||||||||||
| California | $ | 19.9 | $ | 24.6 | $ | (4.7 | ) | (19 | %) | |||||||
| Nevada | 3.0 | 4.1 | (1.1 | ) | (27 | %) | ||||||||||
| Illinois | 3.5 | 4.3 | (0.8 | ) | (19 | %) | ||||||||||
| Arizona | 2.8 | 3.7 | (0.9 | ) | (24 | %) | ||||||||||
| Massachusetts | 0.8 | - | 0.8 | - | ||||||||||||
| Continuing Operations | 30.0 | 36.7 | (6.7 | ) | (18 | %) | ||||||||||
| Discontinued Operations | 3.6 | 7.3 | (3.7 | ) | (51 | %) | ||||||||||
| Total Revenue | $ | 33.6 | $ | 44.0 | $ | (10.4 | ) | (24 | %) | |||||||
Overall, across all markets, for the periods presented, we experienced declines in revenue across all markets.
In California, we experienced a decline of $(4.7) million or (19%) over the same prior year period primarily driven by lower basket size, inconsistent traffic to the stores which was slightly partially offset by flat conversion rates. We believe we were also affected by the status of the cannabis supply in this State. California is currently experiencing high levels of cannabis production which we believe has flooded the illegal market with quality cannabis flower that illicit operators are offering to cannabis consumers at lower selling prices. In addition, the increase in new dispensaries within key markets, especially West Hollywood, and the more aggressive promotional cadence these dispensaries are promoting, has resulted in a saturated market wherein the California cannabis consumer has an increased number of choices for cannabis products at discounted pricing. During this first fiscal quarter, we increased our focus on product portfolio and product selection, expanding vendor relationships, engaging in allowable marketing strategies, and continued efforts to develop our private label products.
In Nevada, revenue for the three months declined $(1.1) million or (27%). We experienced a decline in basket size as well as traffic and conversion rates. Nevada noted an overall decline in legal cannabis sales primarily related to a maturing industry, lower disposable income and a revenue base heavily reliant on tourism.
In Illinois, revenue declined $(0.8) million or (19%). We continue to face market pressure from additional licenses issued by surrounding municipalities as part of Illinois’ efforts to promote equality and accessible locations for the consumer. We have made great efforts in testing new promotional messaging that, if marketed properly, can increase foot traffic and revenue.
In Arizona, revenue for the period decreased $(0.9) million or (24%). This decrease resulted from a decline in medical-use sales because of a maturing recreational cannabis industry. Arizona is also experiencing an increase in new dispensary openings, that similar to California, has resulted in a saturated market. Exacerbating the increase in dispensary openings, is the increase in aggressive promotional cadences by these dispensaries. We continue our efforts to finding the optimal product selection that can meet the demands of both medical and recreational customers as well as planning for additional private label products from our own cultivation facility in Mesa.
40
In Massachusetts, our store near Fenway Park opened December 2021 with no comparable sales for this reporting period.
During our first fiscal quarter, we completed the sale of our Florida-based assets. We continue to hold for sale our New York-based assets which are presented as discontinued operations.
Cost of Goods Sold and Gross Profit
Cost of goods sold for the three months ended September 24, 2022 was $15.2 million compared to $19.3 million, a decrease of $(4.1) million, or (21%), for the three months ended September 25, 2021. Gross profit for the fiscal first quarter was $14.9 million, representing a gross margin of 50%, as compared to $17.4 million, representing a gross margin of 47%, for the same prior year period. The improvement in gross margin resulted from our continuous efforts to develop vendor programs that reduced our cost of goods sold, as well as our success in lowering costs of production at our cultivation centers.
Operating Expenses
Operating expenses for the three months ended September 24, 2022 were $20.5 million, a decrease of $(21.3) million, or (51%), compared to $41.7 million for the three months ended September 25, 2021. These changes were attributable to the factors discussed below.
General and administrative expenses (“G&A”) for the three months ended September 24, 2022 were $17.8 million, compared to $32.6 million for the same prior year period. The overall decrease in the three months period is primarily due to the Company’s corporate cost saving strategy. Key drivers of the decrease in G&A include reductions in professional fees ($6.1) million, payroll expenses ($3.0) million, licenses and fees ($1.5) million, deal costs ($1.2) million and rental payments ($1.1) million. Management continues to focus on reducing company-wide G&A. We expect G&A will continue to decrease in fiscal year 2023 as compared to prior year.
Sales and marketing expenses remained relatively consistent for the three months ended September 24, 2022 and September 25, 2021 in the amount of $0.4 million and $0.6 million, respectively.
Depreciation and amortization for the three months ended September 24, 2022 was $3.9 million, compared to $5.8 million for the same prior year period. The overall decrease is attributable to the impairment of assets recorded in Q4 2022 and delay in new capital projects. We are currently evaluating the long-term benefits of continuing to pursue the build out of some of our locations not yet opened or constructed. We are in negotiations with the landlords of our unfinished locations in California, Illinois and Massachusetts in an effort to reach the best outcome for all parties including the communities that live and work near these unfinished locations possibly deterring from market values.
Impairment expense for the three months ended September 24, 2022 was $1.7 million, compared to $0.4 million for the three months ended September 25, 2021. During the current period, the Company wrote off approximately $1.7 million of construction in progress.
Other operating (income) expense for the three months ended September 24, 2022 was $(2.6) million, compared to $2.2 million for the three months ended September 25, 2021. The decrease of $(4.8) million in other operating (income) expense was primarily due to a decrease of $(2.0) million in restructuring expenses coupled with a gain on lease termination of $1.6 million and sublease income of $1.5 million recognized during the fiscal first quarter of 2023, versus none in the comparative period.
41
Non-Operating Expense
Non-operating expense for the three months ended September 24, 2022, was $12.4 million, compared to $2.2 million in the prior year period. The increase in non-operating expense was primarily due a $10.2 million gain on extinguishment of debt recognized in prior fiscal first quarter versus none in the current period. This was offset by a $(4.7) million decrease in accretion of debt discount due to the principal repayment of $31.6 million on the Senior Secured Term Loan during the fiscal first quarter of 2023 and a $(2.9) million decrease in change in fair value of derivatives.
Provision for Income Taxes
MedMen is subject to income taxes in the jurisdictions in which it operates and, consequently, income tax expense is a function of the allocation of taxable income by jurisdiction and the various activities that impact the timing of taxable events. As we operate in the legal cannabis industry, we are subject to the limits of Internal Revenue Code (“IRC”) Section 280E under which we are only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E and a higher effective tax rate than most industries. However California does not conform to IRC Section 280E and, accordingly, we deduct all operating expenses on MedMen’s California Franchise Tax Returns.
The provision for income taxes for the three months ended September 24, 2022 was $2.2 million, compared to the provision for income tax expense of $19.7 million for the three months ended September 25, 2021, primarily due to the Company’s forecasted income and related IRC Section 280E expenditures.
Net Loss
Net loss from continuing operations for the three months ended September 24, 2022 was $20.3 million, a decrease of $(25.9) million compared to $46.2 million for the three months ended September 25, 2021. For the fiscal first quarter of 2023, net loss from continuing operations was favorably impacted by the Company’s continued efforts to optimize selling, general and administrative costs and right-size the Company’s corporate infrastructure.
Non-GAAP Financial Measures
EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations are financial measures that are not defined under GAAP. We define EBITDA as net income (loss), or “earnings”, before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA before: (i) transaction costs and restructuring costs; (ii) non-cash share-based compensation expense; (iii) fair value changes in derivative liabilities and contingent consideration; (iv) (gains) losses on disposal of assets, assets held for sale, extinguishment of debt and lease terminations; and (v) other one-time charges for non-cash operating costs. These financial measures are metrics that have been adjusted from the GAAP net income (loss) measure in an effort to provide readers with a normalized metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. Other companies in our industry may calculate this measure differently, limiting their usefulness as comparative measures.
42
Reconciliations of GAAP Measures to Non-GAAP Financial Measures
The table below reconciles Net Loss to EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations for the periods indicated.
| Three Months Ended | ||||||||
| September 24, | September 25, | |||||||
| ($ in Millions) | 2022 | 2021 | ||||||
| Net Income (Loss) | $ | 4.0 | $ | (60.6 | ) | |||
| Less: Net (Income) Loss from Discontinued Operations, Net of Taxes | (24.3 | ) | 14.4 | |||||
| Add (Deduct) Impact of: | ||||||||
| Net Interest and Other Financing Costs (1) | 11.6 | 14.5 | ||||||
| Provision for Income Taxes | 2.2 | 19.7 | ||||||
| Amortization and Depreciation | 4.0 | 6.3 | ||||||
| Total Adjustments | 17.8 | 40.5 | ||||||
| EBITDA from Continuing Operations | $ | (2.5 | ) | $ | (5.7 | ) | ||
| Add (Deduct) Impact of: | ||||||||
| Transaction Costs & Restructuring Costs | $ | 0.9 | $ | 4.0 | ||||
| Share-Based Compensation | 0.9 | 1.6 | ||||||
| Change in Fair Value of Derivative Liabilities | 0.8 | (2.1 | ) | |||||
| Change in Fair Value of Contingent Consideration | (0.9 | ) | - | |||||
| (Gain) Loss on Lease Termination | (1.6 | ) | - | |||||
| (Gain) Loss on Extinguishment of Debt | - | (10.2 | ) | |||||
| (Gain) Loss from Disposal of Assets | 0.2 | - | ||||||
| Sublease Income | (1.5 | ) | - | |||||
| Impairment Expense | 1.7 | 0.4 | ||||||
| Other Non-Cash Operating Costs | - | (0.2 | ) | |||||
| Total Adjustments | $ | 0.5 | $ | (6.5 | ) | |||
| Adjusted EBITDA from Continuing Operations | $ | (2.0 | ) | $ | (12.2 | ) | ||
| (1) | For the current period, net interest and other financing costs now include accretion of debt discount and loan origination fees of $1.6 million for the three months ended September 24, 2022. The prior year amount of $6.3 million for the three months ended September 25, 2021 have been reclassified for consistency with the current year presentation. Accretion of debt discount was previously excluded from the reconciliation of Net Loss to EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations. |
43
EBITDA from Continuing Operations represents the Company’s current operating profitability and ability to generate cash flow and includes significant non-cash operating costs. Considering these adjustments, the Company had EBITDA from Continuing Operations of $(2.5) million for the three months ended September 24, 2022 compared to $(5.7) million for the comparative prior period. The change in EBITDA from Continuing Operations was primarily due to the Company’s continued cost-saving strategies and lower operating costs at the cultivation facilities of California and Nevada as a result of the licensing and management agreement which includes lower rents.
For the three months ended September 24, 2022, Adjusted EBITDA from Continuing Operations was $(2.0) million compared to $(12.2) million for the three months ended September 25, 2021. The improvement is primarily due to the decrease in general and administrative expenses. The financial performance of the Company is expected to further improve as the Company works towards profitability and coupled with significant deleveraging of its balance sheet, will reposition the Company for growth.
Refer to Item 2 “Liquidity and Capital Resources” for further discussion of management’s future outlook.
Cash Flows
The following table summarizes the Company’s consolidated cash flows for the three months ended September 24, 2022 and September 25, 2021:
| Three Months Ended | ||||||||||||||||
| September 24, | September 25, | |||||||||||||||
| ($ in Millions) | 2022 | 2021 | $ Change | % Change | ||||||||||||
| Net Cash Used in Operating Activities | $ | (9.6 | ) | $ | (23.0 | ) | $ | 13.4 | (58 | %) | ||||||
| Net Cash Provided by (Used in) Investing Activities | 51.5 | (3.6 | ) | 55.1 | (1,531 | %) | ||||||||||
| Net Cash (Used in) Provided by Financing Activities | (31.6 | ) | 93.2 | (124.8 | ) | (134 | %) | |||||||||
| Net Increase in Cash and Cash Equivalents | 10.3 | 66.6 | (56.3 | ) | (85 | %) | ||||||||||
| Cash Included in Assets Held for Sale | - | (0.3 | ) | 0.3 | 100 | % | ||||||||||
| Cash and Cash Equivalents, Beginning of Period | 10.8 | 11.6 | (0.8 | ) | (7 | %) | ||||||||||
| Cash and Cash Equivalents, End of Period | $ | 21.1 | $ | 77.9 | $ | (56.8 | ) | (73 | %) | |||||||
Cash Flow from Operating Activities
Net cash used in operating activities was $9.6 million for the three months ended September 24, 2022, a decrease of $13.4 million, compared to $23.0 million for the three months ended September 25, 2021. The decrease was primarily driven by the decrease in general and administrative expenses as described in “Results of Operations” above.
Cash Flow from Investing Activities
Net cash provided by investing activities was $51.5 million for the three months ended September 24, 2022 compared to the $3.6 million of net cash used in investing activities in the prior year. This was primarily due to the $51.5 million in cash proceeds from the sale of the Company’s operations in the state of Florida during the current period.
44
Cash Flow from Financing Activities
Net cash used in financing activities was $31.6 million for the three months ended September 24, 2022 compared to $93.2 million net cash provided by financing activities for the three months ended September 25, 2021. During the current period, the Company used $31.6 million of the cash proceeds from the sale of its Florida-based operations to make principal repayments on the Senior Secured Term Loan. Whereas during the comparative prior period, the Company completed a private placement with Serruya Private Equity Inc. (“SPE”) resulting in an equity investment of $100.0 million.
Financial Condition and Going Concern
As of September 24, 2022, the Company had cash and cash equivalents of $21.1 million and working capital deficit of $134.9 million. The Company has incurred net losses from continuing operations of $20.3 million and $46.2 million for the three months ended September 24, 2022 and September 25, 2021, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.
The Company plans to continue to fund its operations through the implementation of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with our master lease landlord and other landlords, divesture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue strategy of market expansion and retail revenue growth. We also need to obtain an extension or a refinancing of our debt-in-default with the secured senior lender. Our annual operating plan for fiscal year 2023 estimates we will be able to manage our ongoing operations. However, our cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, we expect to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing.
As of September 24, 2022, the accompanying Consolidated Financial Statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.
The following table summarizes certain aspects of the Company’s financial condition as of September 24, 2022 and June 25, 2022:
| September 24, | June 25, | |||||||||||||||
| ($ in Millions) | 2022 | 2022 | $ Change | % Change | ||||||||||||
| Cash and Cash Equivalents | $ | 21.1 | $ | 10.8 | $ | 10.3 | 95 | % | ||||||||
| Total Current Assets | $ | 98.7 | $ | 161.5 | $ | (62.8 | ) | (39 | %) | |||||||
| Total Assets | $ | 251.1 | $ | 323.2 | $ | (72.1 | ) | (22 | %) | |||||||
| Total Current Liabilities | $ | 233.6 | $ | 319.6 | $ | (86.0 | ) | (27 | %) | |||||||
| Notes Payable, Net of Current Portion | $ | 74.9 | $ | 206.4 | $ | (131.5 | ) | (64 | %) | |||||||
| Total Liabilities | $ | 564.7 | $ | 641.7 | $ | (77.0 | ) | (12 | %) | |||||||
| Total Shareholders’ Equity | $ | (313.6 | ) | $ | (318.5 | ) | $ | 4.9 | (2 | %) | ||||||
| Working Capital Deficit | $ | (134.9 | ) | $ | (158.1 | ) | $ | 23.2 | (15 | %) | ||||||
45
In August 2022, the Company completed the sale of its operations in the state of Florida at the final sales price of $67,000,000 which comprised of $63,000,000 in cash and $4,000,000 in liabilities to be assumed by the Buyer. The Buyer made a cash payment of $40,000,000 at closing, $11,500,000 on September 15, 2023, and is required to make an additional installment payment of $11,500,000 on or before March 15, 2023. During the fiscal third quarter of 2022, net proceeds to the Company were $19,558,947 after a principal repayment of $31,599,999 on the Senior Secured Term Loans with Hankey Capital. The final cash payment of $11,500,000 remains due and receivable as of September 24, 2022. The Senior Secured Term Loans remains outstanding and in default as of September 24, 2022.
The $23.2 million improvement in working capital deficit was primarily related to the $31.6 million principal repayment on the Senior Secured Term Loans that matured on July 31, 2022 and August 1, 2022. The Company’s working capital will be significantly impacted by continued operations and growth in retail operations and the continued stewardship of the Company’s financial resources. The ability to fund working capital needs will also be dependent on the Company’s ability to raise additional debt and equity financing and execute cost savings plans.
Liquidity and Capital Resources
The primary need for liquidity is to fund working capital requirements of the business, including operationalizing existing licenses, capital expenditures, debt service and acquisitions. The primary source of liquidity has primarily been private and/or public financing and to a lesser extent by cash generated from sales. The ability to fund operations, to make planned capital expenditures, to execute on the growth/acquisition strategy, to make scheduled debt and rent payments and to repay or refinance indebtedness depends on the Company’s future operating performance and cash flows, which are subject to prevailing economic conditions and financial, business and other factors, some of which are beyond its control. Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure.
Off-Balance Sheet Arrangements
The Company has no material undisclosed off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations, financial condition, revenues or expenses, liquidity, capital expenditures or capital resources that are material to investors.
Critical Accounting Policies, Significant Judgments and Estimates and Recent Accounting Pronouncements
There have been no changes in critical accounting policies, estimates and assumptions from the information provided in “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” included in the Form 10 for the fiscal year ended June 25, 2022 that have a significant effect on the amounts recognized in the Condensed Consolidated Financial Statements as of and for the fiscal quarter ended September 24, 2022. See “Note 2 – Summary of Significant Accounting Policies” in the Condensed Consolidated Financial Statements in Item 1 for recently adopted accounting standards. For more information on the Company’s critical accounting estimates, refer to the “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the Annual Report on Form 10-K for the fiscal year ended June 25, 2022. In addition, a detailed description of our critical accounting policies and recent accounting pronouncements are detailed in Part I, “Item 8. Financial Statements and Supplementary Data” of the Annual Report on Form 10-K for the fiscal year ended June 25, 2022.
46
Transactions with Related Parties
As of September 24, 2022 and June 25, 2022, there were no amounts due from or due to related parties that were recorded in the Consolidated Balance Sheets. Refer to “Note 19 – Related Party Transactions” of the Consolidated Financial Statements for the three months ended September 24, 2022 in Item 1.
The Company’s Board of Directors each receive quarterly fees of $200,000 of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares.
Senior Secured Convertible Credit Facility
As of September 24, 2022, the Company has drawn down a total of $165.0 million on the Convertible Facility, has accrued paid-in-kind interest of $45.2 million with an aggregate weighted average conversion price of approximately $0.24 per share, and an aggregate of 196,327,593 warrants with a weighted average exercise price of $0.17 per share.
Emerging Growth Company Status
The Company is an “emerging growth company” as defined in the Section 2(a) of the Exchange Act, as modified by the Jumpstart Our Business Start-ups Act of 2012, or the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 13(a) of the Exchange Act for complying with new or revised accounting standards applicable to public companies. The Company has elected to take advantage of this extended transition period and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Information not required to be filed by smaller reporting companies.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Pursuant to Rules 13a-15(b) and 15-d-15(b) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), as of September 24, 2022, the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer of the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report.
The term “disclosure controls and procedures”, as defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Based upon that evaluation and the identification of the material weakness described herein, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective, at the reasonable assurance level, as of the end of our last fiscal year end, June 25, 2022, and continues as such as of the end of the period covered by this report.
47
Changes in Internal Control Over Financial Reporting
For fiscal year 2022, management identified a material weakness determining that the Company’s financial recordkeeping process was deficient and that it does not have effective controls over the period-end reconciliation process. The reconciliation process was not being performed in a manner that will detect and correct errors on a timely basis, including:
| ● | general ledgers are not being reviewed regularly for assets that may not be recoverable or viable, | |
| ● | review procedures for balance sheet account reconciliations and manual journal entries were not performed, and | |
| ● | some accounts and balances are not being reconciled regularly, and/or account reconciliations that are being completed do not properly address or adjust reconciling items. |
Management plans to implement measures designed to improve its internal control over financial reporting to remediate material weaknesses described above by standardizing the monthly reconciliation process for material accounts and balances with formalized procedures. Material non-standard journal entries recorded in the accounting system will be reviewed for the various applicable accounting assertions including recoverability and validity. While the Company is actively engaged in the implementation of its remediation efforts to address this internal control weakness, the actions we have taken are subject to continued review, supported by confirmation and testing by management. Accordingly, the material weakness will not be considered fully remediated until the new control procedures are implemented for a sufficient period of time and management has concluded that these controls are operating effectively which we anticipate will occur in the ensuing months.
Except as noted above, there were no changes in our internal control over financial reporting during the three months ended September 24, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements attributable to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Assessments of any evaluation of controls’ effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements as a result of error or fraud may occur and not be detected.
48
PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Other than noted below, there have been no material developments during the fiscal quarter covered by this Report for our legal proceedings that were disclosed in our Annual Report on Form 10-K filed on September 9, 2022.
On October 6, 2022 the Company entered into a Settlement and Mutual Release Agreement with Charles Coburn, Daryll DeSantis, Unisys Technical Solutions, LLC and Delsantro Investments LLC in connection with a complaint filed by these parties on May 26, 2020 and counterclaim by the Company (the “Unisys Litigation”). The agreement resolved the Unisys Litigation and preserved the Company’s right to a pro rata distribution from plaintiff and cross defendant Charles Coburn’s bankruptcy estate as may be ordered by the bankruptcy court.
On July 11, 2022 Thor 952 Fulton Street, LLC, an affiliate of Thor Equities Group, filed a complaint in the United States District Court for the Southern District of New York against Future Transactions Holdings, LLC, an affiliate of the Company, MM Enterprises USA, LLC, and the Company seeking approximately $950,960 in damages relating to a lease of commercial property located in Illinois, which lease specified use as a cannabis dispensary, claiming diversity jurisdiction. On September 16, 2022 the Company moved to dismiss the case on the basis that the subject matter of the contract was illegal under federal law, and plaintiffs thereafter moved for a voluntary dismissal. On October 17, 2022 the United States District court granted plaintiff’s motion for voluntary dismissal of the complaint without prejudice. On October 19, 2022 Future Transactions Holdings, LLC, MM Enterprises USA, LLC, and the Company filed a complaint under the federal Declaratory Judgment Act against Thor 942 Fulton Street, LLC.
ITEM 1A. RISK FACTORS.
Smaller reporting companies are not required to provide the information required by this Item.
ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
See discussion of Senior Secured Term Loan in “Note 10 – Notes Payable” under Part I, “Item 1. Notes to Condensed Consolidated Financial Statements”, which is incorporated in this item by reference.
ITEM 4. MINE SAFETY DISCLOSURE
Not applicable.
49
ITEM 5. OTHER INFORMATION
By resolution dated as of September 21, 2022, as consideration for Mr. Record’s service to the Company since April 24, 2022, when he was appointed as Chief Executive Officer, including successfully guiding the Company through the sale of its Florida assets, the Board effectively approved a cash bonus of $171,429. This payment represents the amount already due to Mr. Record pursuant to the terms of his employment entered at the time of his appointment; except that he shall now receive cash in lieu of RSUs for the period beginning on the date of his appointment through and until the date of the Board resolution. The Board also approved the grant to Mr. Record under the Company’s 2018 Stock and Incentive Plan of $3,000,000 worth of options with a term of five years to purchase Subordinate Voting Shares at an exercise price per share of $0.051968 and with one-third vesting on the date of grant and one-third vesting on each of April 24, 2023 and April 24, 2024. The resolution directs the Company to determine the number of options to be issued through the application of the Black Scholes option pricing model. The options will vest automatically upon a change of control or Mr. Record’s termination as CEO, unless the Board determines that Mr. Record is terminated based on his conduct or performance. A change of control generally includes the acquisition of 50% of the voting securities of the Company, a merger, or sale of all or substantially all of the Company’s assets. Pursuant to his employment terms, Mr. Record will continue to receive an annual salary of $416,000 and is eligible to receive up to an additional $8,000 per week during his service as CEO (the “Bonus”), one half of which will be paid in cash and one half will be paid in RSUs. The Bonus will be paid quarterly at the approval of the Board and not contingent on any specific requirements unless the Board determines reasonably that Mr. Record’s performance did not meet minimal acceptable standards or Mr. Record is terminated based on conduct or performance. The number of RSUs granted will be based on the trailing 10-day volume weighted average price of the Subordinate Voting Shares trading on the Canadian Securities Exchange or any National Securities Exchange prior to the date of grant.
On October 18, 2022, the Company’s Board of Directors approved a change to director compensation with regards to calculating the number of Subordinate Voting Shares issued to non-employee directors. The Company’s non-employee directors will continue to receive an annual fee of $250,000, of which one-third is paid in cash on a quarterly basis and two-thirds is paid in Subordinate Voting Shares. Each director will now receive on an annual basis 3,453,802 Subordinate Voting Shares, of which 864,200 Subordinate Voting Shares will vest quarterly, with retroactive effect to April 21, 2022.
In February 2022, the Company executed the Sixth Modification extending the maturity date of senior secured term loan facility (the “Facility”) with Hankey Capital and Stable Road Capital (the “Lenders”) to July 31, 2022 with respect to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the “Term Loans”). The Sixth Modification makes no modification to the current interest rate. The Sixth Modification provides that the definitive documentation with respect to the conditional purchase of the Term Loans by Superhero Acquisition, L.P., an existing lender under the Company’s Senior Secured Convertible Purchase Agreement dated August 7, 2021, must be entered within 45 days or the stated maturity date of the Term Loans become due. The Sixth Modification requires that the Company make a mandatory prepayment of at least $37,500,000 in the event the sale of certain assets and imposes covenants in regards strategic actions the Company must implement if it is unable to pay the Term Loans by the extended stated maturity date. During the three months ended September 24, 2022, in connection with the sale of the Company’s Florida-based operations, the Company made a principal repayment of $31,599,999 with proceeds from the sale. The Facility remains in default as of September 24, 2022 and the Company is in ongoing discussions with the Lenders.
50
ITEM 6. EXHIBITS
| * | This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. |
51
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 3, 2022 | MEDMEN ENTERPRISES INC | |
| /s/ Ana Bowman | ||
| By: | Ana Bowman | |
| Its: | Chief Financial Officer | |
52